Novartis tender offer for MorphoSys commences
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
A significant proportion of healthcare professionals still tend to favor branded drugs
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Subscribe To Our Newsletter & Stay Updated